Backing Biogen, 75+ House Republicans call on CMS to abandon its decision to limit amyloid-targeted Alzheimer's drugs to trials

Top Republicans are calling on HHS “to abandon and re-propose” a draft national coverage decision from CMS on anti-amyloid Alzheimer’s drugs, which seeks to restrict the use of such drugs to clinical trials until their benefits can be established.

Cathy McMorris Rodgers (WA), Kevin Brady (TX), Brett Guthrie (KY), and 75 others in the House sent a letter Wednesday to HHS Secretary Xavier Becerra, urging him to instead provide “reasonable access to FDA-approved [Alzheimer’s] treatments for a broader population of Medicare beneficiaries.”